RecruitingSolid Tumors
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
You may qualify if…
- ✓ Written informed consent.
- ✓ Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
- ✓ ECOG performance status score of 0 or 1.
- ✓ Has been treated with at least one line of systemic therapy for that tumor type and stage.
- ✓ Have documentation of confirmed TP53 Y220C mutation.
- ✓ At least 1 measurable lesion per RECIST v1.1.
- ✓ Adequate hematological, renal and hepatic function and appropriate coagulation condition.
- ✓ Able to swallow and retain orally administered medication.
You may not qualify if…
- ✕ Active brain or spinal metastases or primary CNS tumor.
- ✕ Active infection requiring systemic treatment within 7 days.
- ✕ Active HBV or HCV.
- ✕ Any severe and/or uncontrolled medical conditions.
- ✕ LVEF ≤50% assessed by ECHO or MUGA.
- ✕ QTcF \> 470 msec.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06386146 · last updated 2026-05-22